Activity of topotecan in retinoblastoma

Ophthalmic Genetics

Volumn 25, Issue 1, 2004, Pages 37-43

  Chantada, Guillermo L ^a   Fandiño, Adriana C ^a   Casac, Sandra J ^a   Mato, Gabriel ^a   Manzitti, Julio ^a   Schvartzman, Enrique ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Children; Eye tumors; Retinoblastoma; Topotecan

Indexed keywords

CARBOPLATIN; ETOPOSIDE; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; FEVER; HUMAN; INFECTION; MALE; MEDICAL DOCUMENTATION; METASTASIS; OPHTHALMOSCOPY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REFRACTORY PERIOD; RELAPSE; RETINOBLASTOMA; TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETINAL NEOPLASMS; RETINOBLASTOMA; TOMOGRAPHY, X-RAY COMPUTED; TOPOTECAN;

EID: 1942518815     PISSN: 13816810     EISSN: None     Source Type: Journal    
DOI: 10.1076/opge.25.1.37.28996     Document Type: Article

References (12)

1. Chantada G, Fandiño A, Mato G, et al. A phase II window of idarubicin in children with extraocular retinoblastoma. J Clin Oncol. 1999;17:1847-1850.
2. Doz F, Neuenshwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societé Française d'Oncologie Pédiatrique. J Clin Oncol. 1995;13:902-909.
3. Kretschmar C, Kletzel M, Murray K. Upfront phase II therapy with taxol (txl) and topotecan (topo) in untreated children (>365 days) with disseminated neuroblastoma (NB). A Pediatric Oncology Group Study (Abstract). Med Pediatr Oncol. 1995;25:243.
4. Pappo A, Lyden E, Breneman J, et al. Upfront window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 2001;19:213-219.
5. Nitiss JL, Wang JC. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol. 1996;50:1095-1102.
6. Frangoul H, Ames M, Mosher R, et al. Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin Cancer Res. 1999;5:3956-3962.
7. Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II Study. J Pediatr Hematol Oncol. 1998;20:315-318.
8. Grabowski E, Abramson D. Intraocular and extraocular retinoblastoma. Hematol Oncol Clin North Am. 1987;1:721-735.
9. Pratt CB, Crom DB, Howarth C. The use of chemotherapy for extraocular retinoblastoma. Med Pediatr Oncol. 1985;13(6):330-333.
10. Baker SD, Heideman RL, Crom WR, et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol. 1996;37(3):195-202.
11. Blaney SM, Heideman R, Berg S, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003;21: 143-147.
12. Chan H, Canton M, Gallie B. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res. 1989;9:469-474.